Little by little, more details about Some treatments that may be effective against COVID-19. Now, a study published in the journal mBio claims that the vaccine against measles, mumps, and rubella (known as MMR), could provide certain protection against disease.
In this analysis, experts show that IgG antibody levels are inversely correlated with severity in recovered coronavirus patients previously vaccinated with the MMR II remedy. This cure contains the strain of Jeryl Lynn mumps (level B) and the rubella strain Wistar RA 27/3.
Jeffrey E. Gold, lead author of the study, explains that “we found a statistically significant inverse correlation between mumps titre levels and COVID-19 severity in people under 42 who have been vaccinated against MMR II. This is in addition to other associations showing that MMR vaccine may be protective against COVID-19. “
“Too could explain why children have a rate of COVID-19 cases much lower than adults, as well as a much lower death rate. Most of the children receive their first MMR vaccine around 12 to 15 months of age and a second between 4 and 6 years of age, “adds Gold.
Rehearsal with 80 people
Researchers they divided 80 people into 2 groups. The first, formed by 50 subjects, would have MMR antibodies from the MMR II vaccine. The second, composed of 30 individuals, had no SPR II vaccination record and would mainly have SPR antibodies from other sources, such as previous diseases of measles, mumps, or rubella.
Thus, the researchers found an inverse correlation between mumps antibodies and the severity of coronavirus in the MMR II group. But nevertheless, there were no significant links between mumps antibodies and the severity of the pathogen in the comparison group, between mumps antibodies and age in the MMR II group, or between gravity and measles or rubella antibodies in either group.